FACT / 29/09/2025 by TLJ

Johnson & Johnson Q1 2025 Earnings Report

  • N ews (0)
  • N ews (0)

Johnson & Johnson reported Q1 2025 sales of $21.9 billion, a 2.4% increase year-over-year. Adjusted EPS rose 2.2% to $2.77. The pharmaceutical segment led growth with a 4.2% operational increase, while medical devices and consumer health segments also saw positive results. The company is on track to achieve net cost savings of approximately $4.5 billion by the end of 2025

  • Share: